Biotechnology is part of our work in Life Sciences.
Over our more than 50 years in practice, Finnegan has worked with biotech pioneers to develop and execute successful intellectual property strategies, including patenting ground-breaking advancements, enforcing patents in litigation, and defending against claims of infringement or ownership by others. We successfully represented Eli Lilly and Company in a lawsuit involving the first marketed product produced by biotechnology—human insulin—and have provided counseling or litigation services in a range of biotechnologies, such as automated DNA sequencing, the cloning of Dolly the sheep, noninvasive methods for detecting fetal aneuploidy, and platform antibody design.
Strong IP protection has been essential to advancing the biotech industry and remains key to its continued growth. As an IP law firm comprised of scientists and biotech engineers, Finnegan is structured to stay abreast of rapid advancements in science and changing legal issues in this fast-paced, multidisciplinary industry.
As our biotechnology clients make exciting breakthroughs in ways we have yet to imagine, we help by:
We work with clients advancing discoveries in established as well as emerging areas, including:
2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre
IPR2022-01200, PGR2022-00051, PTAB, Judges Newman, Snedden, Wisz
22-2232, Fed. Cir.
PGR2022-00037, PTAB, Judges Newman, Obermann, Worth
IPR2022-00738, -00739, -00796, PTAB, Judges Cotta, Wisz, Worth
1:21-cv-10954, D. Mass., Judge Burroughs
T 0527/17, EPO
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Webinar
February 15, 2024
Webinar
Webinar
Navigating Your Life Sciences Opposition: Tips for Best Practice When You Are Opposing or Opposed
December 12, 2023
Webinar
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Press Release
Finnegan Continues to Hold Top-Tier LMG Life Sciences 2022 Rankings
September 22, 2022
Press Release
ITC Determines Healthgen’s Medium Grade Products Did Not Infringe Ventria’s Patent
September 16, 2022
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.